Two drugs are covered in this quarterly column. Faricimab-svoa (Vabysmo) for Macular Degeneration and Diabetic Macular Edema and Omidenepag Isopropyl (Omlonti) for Glaucoma and Ocular Hypertension.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.4140/TCP.n.2023.497 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Faricimab Treatment of Polypoidal Choroidal Vasculopathy Resistant to Intravitreal Ranibizumab Injections and Ranibizumab Port Delivery (Susvimo).
J Vitreoretin Dis
August 2024
Vitreoretinal Surgery, Acuity Eye Group, Los Angeles, CA, USA.
To report a case of polypoidal choroidal vasculopathy (PCV) recalcitrant to treatment with ranibizumab and with a ranibizumab port delivery system (Susvimo) but responsive to faricimab-svoa. A case and its findings were analyzed. A 69-year-old Filipino man with PCV in the left eye was treated for 2 years with multiple ranibizumab intravitreal (IVT) injections followed by ranibizumab port delivery combined with rescue ranibizumab IVT injections, with no significant response clinically or on imaging.
View Article and Find Full Text PDFChanges in Internet Search Behavior After a Direct-to-Consumer Advertising Campaign for Faricimab-svoa.
J Vitreoretin Dis
October 2024
Retina Associates of Orange County, Laguna Hills, CA, USA.
To analyze changes in Google search volume after US Food and Drug Administration (FDA) approval and initiation of a direct-to-consumer marketing campaign for faricimab-svoa. Google Trends data between December 26, 2021, and June 17, 2023, were downloaded and searched for terms prominently featured in the marketing campaign, including "wet AMD", "diabetic macular edema", "Vabysmo", and "faricimab-svoa". Data were standardized to the week and the term with the highest search volume, resulting in weekly relative search volumes for each term.
View Article and Find Full Text PDFSubmacular Hemorrhage Rates Following Anti-Vascular Endothelial Growth Factor Injections for Exudative Age-Related Macular Degeneration.
Am J Ophthalmol
October 2024
Department of Ophthalmology, Mayo Clinic (M.R.S.), Rochester, Minnesota, USA. Electronic address:
Purpose: To examine rates of submacular hemorrhage in patients undergoing anti-vascular endothelial growth factor (VEGF) injections, comparing rates between specific anti-VEGF agents.
Design: Retrospective clinical cohort study.
Methods: All patients in the database from January 2015 to November 2023 with a diagnosis of neovascular age-related macular degeneration and accompanying submacular hemorrhage (SMH).
Faricimab-Associated Retinal Vasculitis.
J Vitreoretin Dis
May 2024
The Retina Institute, St. Louis, MO, USA.
To report a case of retinal vasculitis after intravitreal faricimab-svoa injection. A case and its management were reviewed. A 77-year-old woman presented with a painless decrease in visual acuity (VA) to counting fingers after receiving an intravitreal faricimab-svoa injection for neovascular age-related macular degeneration.
View Article and Find Full Text PDFTwo drugs are covered in this quarterly column. Faricimab-svoa (Vabysmo) for Macular Degeneration and Diabetic Macular Edema and Omidenepag Isopropyl (Omlonti) for Glaucoma and Ocular Hypertension.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!